oral semaglutide
Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly’s Pill Shows Modest Results
Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition
Actionable Insights Powered by AI
Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition